retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, & hormone receptor drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the Eli Lilly's Phase 3 data
Pay in 4 interest-free payments of $7.14 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28



























![Diglett (106/165) [Expedition: Base Set]](https://pokemonwonder.com/cdn/shop/products/3b07c167-9257-4cdb-8e16-c3ca5ee42e5c_d4fae2d8-d663-4ceb-b2e3-22970e638ac8_1000x1000.png?v=1696329879)

